EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cure of Alzheimer’s Dementia Requires Addressing All of the Affected Brain Cell Types

Jeffrey Fessel iD

Journal of Clinical Medicine · 04.03.2023 · 12 (5) · 2049

DOI: 10.3390/jcm12052049 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 04.03.2023. Verfasst von Jeffrey Fessel. Beteiligte Einrichtung: Department of Medicine, University of California, San Francisco, CA 94143, USA. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 177 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple genetic, metabolic, and environmental abnormalities are known to contribute to the pathogenesis of Alzheimer’s dementia (AD). If all of those abnormalities were addressed it should be possible to reverse the dementia; however, that would require a suffocating volume of drugs. Nevertheless, the problem may be simplified by using available data to address, instead, the brain cells whose functions become changed as a result of the abnormalities, because at least eleven drugs are available from which to formulate a rational therapy to correct those changes. The affected brain cell types are astrocytes, oligodendrocytes, neurons, endothelial cells/pericytes, and microglia. The available drugs include clemastine, dantrolene, erythropoietin, fingolimod, fluoxetine, lithium, memantine, minocycline, pioglitazone, piracetam, and riluzole. This article describes the ways by which the individual cell types contribute to AD’s pathogenesis and how each of the drugs corrects the changes in the cell types. All five of the cell types may be involved in the pathogenesis of AD; of the 11 drugs, fingolimod, fluoxetine, lithium, memantine, and pioglitazone, each address all five of the cell types. Fingolimod only slightly addresses endothelial cells, and memantine is the weakest of the remaining four. Low doses of either two or three drugs are suggested in order to minimize the likelihood of toxicity and drug–drug interactions (including drugs used for co-morbidities). Suggested two-drug combinations are pioglitazone plus lithium and pioglitazone plus fluoxetine; a three-drug combination could add either clemastine or memantine. Clinical trials are required to validate that the suggest combinations may reverse AD.

Schlagwörter

Stichwörter der Autor:innen

Alzheimer’s dementiaaddress brain cell typescurative treatmentthree drugs—pioglitazone/fluoxetine/clemastinethree drugs—pioglitazone/fluoxetine/fingolimodthree drugs—pioglitazone/fluoxetine/memantinethree drugs—pioglitazone/lithium/clemastinethree drugs—pioglitazone/lithium/fingolimodthree drugs—pioglitazone/lithium/memantinetwo drugs—pioglitazone with fluoxetinetwo drugs—pioglitazone with lithium

Autor:innen und Institutionen

  • Department of Medicine, University of California, San Francisco, CA 94143, USA.

ORCID-Profile: Jeffrey Fessel

Zitieren

APA

Fessel, J. (2023). Cure of Alzheimer’s Dementia Requires Addressing All of the Affected Brain Cell Types. Journal of Clinical Medicine, 12(5), 2049. https://doi.org/10.3390/jcm12052049

Vancouver

Fessel J. Cure of Alzheimer’s Dementia Requires Addressing All of the Affected Brain Cell Types. Journal of Clinical Medicine. 2023;12(5):2049. doi:10.3390/jcm12052049

BibTeX
@article{Fessel2023,
  author = {Fessel, Jeffrey},
  title = {Cure of Alzheimer’s Dementia Requires Addressing All of the Affected Brain Cell Types},
  journal = {Journal of Clinical Medicine},
  year = {2023},
  volume = {12},
  number = {5},
  pages = {2049},
  doi = {10.3390/jcm12052049}
}
Kostenlos starten →